An FDA cybersecurity deficiency letter is not a request for better marketing language. It means the agency cannot verify that your device, software, or postmarket process meets its cybersecurity expectations.
Your response must connect each concern to a controlled change, a named owner, and objective evidence. A defensive explanation will not close the gap. A vague promise to fix the issue in the next release may trigger another review cycle.
Start by understanding the hold, decoding each deficiency, and rebuilding the evidence chain before you submit anything.
Key takeaways
- Treat each deficiency as an evidence problem, not a writing problem.
- Distinguish an RTA decision from an Additional Information request.
- Link every threat to a mitigation, test method, result, and controlled document.
- Prioritize SBOM quality, third-party components, cloud services, and vulnerability management.
- Use the letter to strengthen ownership and technology governance, not only to clear the current review.
What an FDA cybersecurity deficiency letter means
The FDA may issue a deficiency when your premarket submission does not give reviewers enough information to evaluate cybersecurity risk. The issue may involve the device itself, its secure development lifecycle, or your ability to manage vulnerabilities after release.
The FDA cybersecurity guidance sets expectations for the information manufacturers should provide, as outlined in the agency’s medical device cybersecurity guidance. Section 524B of the FD&C Act also establishes cybersecurity responsibilities for certain medical device manufacturers.
Common deficiencies include:
- An incomplete or non-machine-readable software bill of materials
- A threat model that misses interfaces, data flows, or attack paths
- Security controls for encryption and data protection that lack verification results
- Weak authentication and authorization or inadequate device hardening measures
- An incomplete vulnerability management plan
- Missing evidence for cloud-hosted services
- No clear process for third-party software components, including off-the-shelf components
- Penetration testing that does not connect to identified risks
- Postmarket procedures that describe intent rather than an operating process
These are often called stock deficiencies because the FDA sees similar gaps across many submissions. They are not harmless template comments. Each one can add delay, require new testing, or force a broader review of your submission.
RTA and AI requests are not the same
The response path depends on when the FDA identifies the problem.
| Review action | What it means | What you should do |
|---|---|---|
| Refuse to Accept, or RTA | The submission fails an early completeness or acceptance review | Correct the missing content and follow the resubmission process |
| Additional Information request | The FDA has started substantive review and needs clarification or evidence | Answer each question with controlled, traceable support |
| Major deficiency | The submission has a significant unresolved issue that may prevent approval | Treat the response as a coordinated remediation and evidence effort |
For many 510(k) submissions, the FDA’s acceptance review occurs within roughly 15 calendar days. A substantial equivalence pathway does not remove cybersecurity evidence expectations. That short review is not the same as a substantive cybersecurity review.
An AI request usually comes later, after substantive review begins; the reviewer needs more information to complete the assessment. An RTA decision means the submission has not cleared the intake screen under the FDA’s refuse to accept policy. Stakeholders may use “ainn letter” as informal internal shorthand, not an official FDA category. Map it to the formal FDA action before drafting a response.
Do not assume that correcting an RTA item will resolve the technical concern. You still need to review the full submission for related gaps.
How to respond without creating another deficiency
Your first response should not be a letter to the FDA. It should be an internal work plan.
1. Freeze the current submission baseline
Save the exact submitted versions of your cybersecurity plan, SBOM, threat model, risk assessment, architecture diagrams, test reports, and postmarket documents.
Do not allow teams to overwrite those files while remediation is underway. You need to show what the FDA reviewed and what changed afterward.
Record the submission number, letter date, response deadline, document versions, and the person responsible for coordinating the answer. Put the work under your quality management system and change-control process.
2. Break the letter into atomic questions
Recurring stock deficiencies still need to be mapped to the specific facts in the letter. FDA wording can combine several concerns in one paragraph. Separate each concern into a trackable item.
Turn the deficiency matrix into a traceability matrix. Build it around threat modeling and risk assessment, connecting each concern to its threat, risk, mitigation, and evidence.
It should include:
- The FDA’s exact concern
- The affected device function, interface, or component
- The related threat or vulnerability
- The risk rating and business or patient impact
- The proposed mitigation
- The verification or validation method
- The test result and evidence location
- The controlled document, version, and related risk management file
- The accountable owner
- Any remaining risk and rationale
This structure creates traceability. It also exposes gaps early.
If a threat has no mitigation, the response is incomplete. If a mitigation has no test, the response is incomplete. If a test result cannot be tied to a requirement, the response is still incomplete.
3. Assign one accountable owner
A cybersecurity deficiency response often crosses engineering, quality, regulatory affairs, clinical, security, and legal teams. That does not mean ownership should be shared by everyone.
Name one executive owner for the response. Give each technical workstream a responsible lead. Regulatory affairs can manage submission mechanics, but engineering and security leaders must own the accuracy of the technical evidence.
A technology leadership gap becomes visible when everyone contributes, but nobody can answer whether the device is ready to submit. In that situation, a fractional CTO, interim CTO, fractional CISO, or interim CISO may provide the executive coordination missing from the current structure.
You can Get an Executive Technology Clarity Check if the response has become scattered across teams, vendors, and competing priorities.
Fix the evidence chain, not only the document
Many stock deficiencies ultimately reflect failures in the evidence chain. The FDA needs a defensible connection between risk, design decisions, and test results. A polished narrative cannot sit above unresolved technical work.
Your threat modeling and risk assessment should cover the full device environment. Include device functions, users, administrators, update paths, external interfaces, cloud services, mobile applications, networks, and data flows.
Methods such as STRIDE, attack trees, attack graphs, misuse cases, and kill-chain analysis can support a systematic review. The specific method matters less than complete coverage and clear reasoning.
A usable threat model should show:
- What can be attacked
- Who may attack it and through which path
- What could happen if the attack succeeds
- Which control, such as authentication and authorization or device hardening measures, reduces the risk
- How that control was verified
- What residual risk remains
Do not treat penetration testing as a substitute for comprehensive threat modeling. A penetration test may find important weaknesses, but it cannot prove that you identified every relevant threat.
Your controlled response should identify the affected requirement and update or cite the risk management file. Describe the design or process change, then cite the test evidence. Include acceptance criteria, test environment, software version, test date, and result.
A future commitment such as “the manufacturer will add stronger authentication” does not close a deficiency. The FDA needs to know what changed, where it changed, and how you know it works.
Address the gaps that trigger repeat questions
Stock deficiencies often reflect recurring evidence gaps that trigger repeat questions. Address them operationally, not only through revised wording.
Make the SBOM usable
Section 524B requires applicable manufacturers to provide a software bill of materials (SBOM) as part of the cybersecurity information for a cyber device. The purpose is practical. Reviewers need to identify software components, versions, relationships, and known exposure without manually interpreting a document.
A PDF list of packages is difficult to search and maintain. A machine-readable SBOM can be processed, compared with vulnerability databases, and updated when components change.
Use a recognized format such as SPDX or CycloneDX when appropriate. Include stable identifiers, such as package URLs where available, along with versions, suppliers, relationships, and known vulnerabilities.
The software bill of materials should match the software actually evaluated in the submission. The submitted build, production build, and test build should also align. If they differ, explain the differences and their security effect.
Close third-party and cloud gaps
Third-party software components are a frequent source of unanswered questions. Your submission should show who maintains each important component, how you monitor it, and what happens when a vulnerability is disclosed.
Your third-party risk management process should address:
- Component inventory and ownership
- Supplier security expectations
- Vulnerability notification timelines
- Patch and update responsibilities
- Support expiration and end-of-life risk
- Access to source code, logs, or security evidence
- Cloud service boundaries and shared responsibilities
Vendor contracts alone are not a vulnerability management plan. Show the operating process through a defined patch management process. Identify who reviews alerts, who approves patches, how emergency fixes are handled, and how decisions are recorded.
For cloud services, explain authentication and authorization controls, administrative access, data movement, logging, backup, recovery, and service dependencies. Do not assume the FDA will infer these controls from a cloud provider’s general security certification.
Show that security controls work
Authentication and authorization should be tied to device roles and real use cases. Encryption and data protection should identify what is protected, where keys are stored, and how keys are managed.
Device hardening measures should cover unnecessary services, default credentials, exposed ports, debug functions, update mechanisms, and administrative interfaces.
Your postmarket surveillance plan should contain or coordinate a vulnerability management plan. It should name the process owner, intake channels, severity criteria, remediation targets, customer communication steps, and reporting path. A paragraph stating that you “will monitor vulnerabilities” is not enough.
Manage the deadline as a business risk
For many FDA interactions, manufacturers have up to 180 calendar days to respond to an additional information request. The submission may then be withdrawn or otherwise closed. The exact rule depends on the submission type, such as a 510(k) seeking substantial equivalence, and the letter.
Read the letter’s deadline, response instructions, and submission requirements carefully. An FDA eSTAR program response must follow the specified electronic format and instructions. Recurring stock deficiencies can require testing, quality review, document revisions, and final evidence production. Treat 180 days as a hard external constraint, not available project time. Deadline management is a regulatory compliance workstream, not merely a project task.
Set an internal deadline well before the FDA deadline. Build time for failed tests, document corrections, quality approvals, and reviewer questions.
Your response package should be consistent across the submission. Threat modeling and risk assessment must align with the risk table and test reports. The software bill of materials must match the evaluated software build described elsewhere. Authentication and authorization terminology must match the evidence in the security plan and test reports.
Before submission, perform a cross-document review. Look for mismatched versions, inconsistent terminology, missing signatures, unsupported claims, and unresolved residual risk.
Use the response to strengthen leadership visibility
A deficiency letter often exposes more than a product gap. A cluster of stock deficiencies may reveal unclear ownership, weak vendor oversight, or immature technology governance.
After the immediate response, add the remediation work to your technology roadmap. Track open vulnerabilities, control improvements, testing, owners, dates, and accepted risks through a regular operating rhythm.
Your board doesn’t need a technical document dump. It needs board cybersecurity reporting that explains material risks, accountable owners, remediation status, decision thresholds, and tradeoffs. A board-ready technology roadmap can help connect those risks to broader priorities.
The same discipline supports cyber risk reporting to the board, cyber risk appetite, third-party risk reporting, and technology risk oversight. Leaders should know what risk remains, who accepted it, and when the decision will be reviewed.
If the response reveals a wider problem with ownership, priorities, or spend, a technology strategy for CEOs can help put the work back into a business-aligned plan.
FAQs about cybersecurity deficiency letters
What are the most common FDA cybersecurity deficiencies?
Common stock deficiencies include incomplete SBOMs, weak threat models, poor traceability, weak authentication or encryption controls, incomplete vulnerability management, unsupported third-party components, and incomplete postmarket processes. Reviewers may also request stronger evidence for cloud services or security testing.
How long do you have to respond?
The FDA letter states the deadline. Many submission types use a 180-day response window for AI matters, but requirements vary. Confirm the requirement for your submission and set an internal deadline before the FDA date.
Why does the FDA care about a machine-readable SBOM?
A machine-readable SBOM helps reviewers and manufacturers identify components, compare versions, monitor vulnerabilities, and assess software supply chain risk. It also supports postmarket monitoring after the device is released.
What should you do if you cannot complete remediation before the deadline?
Don’t hide the gap or submit unsupported claims. Escalate the issue, document the risk, confirm what evidence is available, and seek regulatory guidance through the proper channel. A narrow, honest response is stronger than a broad promise that testing cannot support.
Respond with evidence and ownership
An FDA deficiency letter becomes harder to resolve when your response is defensive or fragmented. This is especially true when it identifies a major deficiency or relies on future intentions.
Use the letter to create one controlled remediation plan. Tie each FDA concern to a risk, mitigation, test result, document version, and accountable owner. Then check that the full submission tells one consistent story.
The goal is not to say that your device is secure. It is to show how you identified risk, reduced it, tested your controls, and will manage what remains. That evidence builds trust with the FDA, your board, and your leadership team while showing how residual risk is managed.